Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

7.8K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.8K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.8K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

4.8K
No description available
4.8K
RNA Interference01:23

RNA Interference

28.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K
MicroRNAs01:22

MicroRNAs

4.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
MicroRNAs01:22

MicroRNAs

24.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety.

The journal of gene medicine·2026
Same author

PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer.

JCI insight·2026
Same author

Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy.

Future science OA·2026
Same author

MFMINet: Multimodal fusion and cross-layer interaction network for semantic segmentation of high-resolution remote sensing images.

iScience·2026
Same author

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

JCO precision oncology·2026
Same author

Clinical characterization and therapeutic targeting of fusion genes in oncology.

Future oncology (London, England)·2025

Related Experiment Video

Updated: Feb 17, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K

Small interfering RNA for experimental cancer therapy.

Alex W Tong1, Yu-An Zhang, John Nemunaitis

  • 1Baylor University Medical Center, Baylor Sammons Cancer Center, Mary Crowley Medical Research Center, Research Laboratory, 3500 Gaston Avenue, Dallas, TX 75246, USA. alext@baylorhealth.edu

Current Opinion in Molecular Therapeutics
|April 23, 2005
PubMed
Summary

Small interfering RNAs (siRNAs) offer potent gene silencing for cancer therapy. Oncolytic adenoviruses enhance siRNA delivery to tumors, improving efficacy and safety for cancer treatment.

More Related Videos

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

6.1K
DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

21.1K

Related Experiment Videos

Last Updated: Feb 17, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

6.1K
DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

21.1K

Area of Science:

  • Molecular Biology
  • Gene Silencing
  • Cancer Therapeutics

Background:

  • RNA interference (RNAi) utilizes small interfering RNAs (siRNAs) for sequence-specific gene silencing.
  • Synthetic siRNAs are established laboratory tools for target validation, outperforming antisense oligonucleotides (ASOs) in consistency and efficacy.
  • Therapeutic applications of siRNA are being explored for infectious diseases and cancer, showing promise in preclinical studies.

Purpose of the Study:

  • To explore the therapeutic potential of siRNA in cancer treatment.
  • To address the challenges of siRNA delivery and off-target effects in cancer therapy.
  • To evaluate the use of oncolytic adenoviruses as a carrier system for siRNA delivery.

Main Methods:

  • Review of in vitro and in vivo studies on siRNA efficacy in cancer.
  • Discussion of pharmacokinetic limitations and off-target activity of siRNA.
  • Exploration of oncolytic adenoviral delivery systems for siRNA.

Main Results:

  • siRNA effectively silences genes crucial for tumor growth, metastasis, angiogenesis, and chemoresistance, leading to tumor suppression.
  • siRNA therapy faces challenges in reaching target cells and potential off-target effects.
  • Oncolytic adenoviral delivery demonstrates potential for localized, renewable siRNA expression within tumors.

Conclusions:

  • Oncolytic adenoviral delivery of siRNA offers a promising strategy to overcome delivery barriers and enhance antitumor effects.
  • This approach combines viral oncolysis with siRNA-mediated oncogene silencing for additive therapeutic benefits.
  • The established clinical safety profile of adenoviruses supports their use as a delivery platform for siRNA cancer therapy.